Please assess the completion status of the following clinical trial:

Trial Title: CAndesartan vs LIsinopril Effects on the BRain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. age: 55 years or older;~2. Hypertension: SBP≥140 mm Hg or DBP≥ 90 mm or receiving antihypertensive medications.~3. Executive MCI will be defined using these criteria:~   1. The Montreal Cognitive Assessment (MoCA) score less than or equal to 26~  2. Executive dysfunction: A performance at the 10th percentile or below on at least one of four screening tests for executive function: Trail Making Test, Part B (TMT-B), modified Stroop interference, Digit Span and Digit Sequencing, and Letter fluency.~  3. Minimal Functional limitation as reflected by the Functional Assessment Questionnaire (FAQ)≤7~Exclusion Criteria:~1. Intolerance to study drugs;~2. SBP \>200 or DBP \>110 mm Hg;~3. Renal disease or hyperkalemia~4. Active medical or psychiatric problems~5. Uncontrolled congestive heart failure;~6. History of stroke in the past 3 years;~7. Inability to perform the study procedures~8. Women of childbearing potential~9. diagnosis of dementia~10. In those who lack decision capacity, a study surrogate who can sign on their behalf will be required. Since we are enrolling only those with MCI, we anticipate that most participants will have decision capacity~11. Current use of Lithium, as most antihypertensive classes may lead to increased lithium toxic levels.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Candesartan (Type: ACTIVE_COMPARATOR): To achieve blood pressure control, we will use a stepwise protocol as follows: candesartan (blinded) 8mg→ 16mg→ 32mg. Both groups will also receive (unblinded) , if needed to achieve blood pressure control, HCTZ 12.5mg→ 25mg, Amlodipine 2.5mg→ 5mg →10mg and metoprolol succinate extended release 12.5mg→ 25mg→ 50mg. Antihypertensive medications will be increased every 2 weeks until control is achieved.
- Lisinopril (Type: ACTIVE_COMPARATOR): To achieve blood pressure control we will use a stepwise protocol as follows: lisinopril (blinded) 10mg→ 20mg→ 40mg. Both groups will also receive (unblinded), if needed to achieve blood pressure control, HCTZ 12.5mg→ 25mg, Amlodipine 2.5mg→ 5mg→ 10mg and metoprolol succinate extended release 12.5mg→ 25mg→ 50mg. Antihypertensive medications will be increased every 2 weeks until control is achieved.

Based on this trial design, predict the completion outcome and termination type (if applicable).